Biolidics Ltd. (SG:8YY)
SGX:8YY
8YY Stock Chart & Stats
S$0.04
<S$0.01(3.70%)
At close: 4:00 PM EST
S$0.04
<S$0.01(3.70%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume13.75M
Average Volume (3M)412.95K
Market Cap
S$104.01M
Enterprise ValueS$105.86M
Total Cash (Recent Filing)S$557.00K
Total Debt (Recent Filing)S$2.41M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Apr 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,733,441,800
10 Day Avg. Volume410,990
30 Day Avg. Volume412,950
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)58.30
Price to Sales (P/S)16.93
P/FCF Ratio-247.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA near-term but substantial revenue recovery indicates renewed commercial traction and market demand for diagnostic products. If sustained, this growth provides a base to scale fixed-cost absorption, support recurring consumables sales, and validate go-to-market execution over the next 2–6 months.
Asset Base ExpandedAn expanding asset base supports higher inventory, manufacturing capacity, or R&D investment, enabling the company to fulfill larger orders and pursue commercialization. This structural growth in assets underpins operational scaling if cash and margins are managed.
Consumables-driven ModelA business model centered on test kits and per-test consumables creates recurring revenue potential and customer lifetime value. Durable consumables demand tied to installed base can deliver predictable repeat sales and margin improvement as penetration grows.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow means the company cannot self-fund growth and must rely on external financing or equity, constraining strategic flexibility. Continued outflows elevate liquidity and execution risk if revenue or margin trends reverse.
High Leverage, Thin EquityMeaningful leverage versus a slim equity cushion limits balance-sheet resilience and increases refinancing or covenant risk. With modest equity and historical negative equity, the company has reduced capacity to absorb shocks or invest without diluting shareholders or adding debt.
Persistently Loss-makingLarge, ongoing net losses despite revenue improvement show operating leverage and margins are unproven. Failure to convert top-line gains into sustainable profitability raises questions about unit economics, pricing, and cost structure over the medium term.
Biolidics Ltd. News
8YY FAQ
What was Biolidics Ltd.’s price range in the past 12 months?
Biolidics Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Biolidics Ltd.’s market cap?
Biolidics Ltd.’s market cap is S$104.01M.
When is Biolidics Ltd.’s upcoming earnings report date?
Biolidics Ltd.’s upcoming earnings report date is Apr 24, 2026 which is in 15 days.
How were Biolidics Ltd.’s earnings last quarter?
Biolidics Ltd. released its earnings results on Feb 27, 2026. The company reported -S$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.002.
Is Biolidics Ltd. overvalued?
According to Wall Street analysts Biolidics Ltd.’s price is currently Overvalued.
Does Biolidics Ltd. pay dividends?
Biolidics Ltd. does not currently pay dividends.
What is Biolidics Ltd.’s EPS estimate?
Biolidics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biolidics Ltd. have?
Biolidics Ltd. has 1,733,441,800 shares outstanding.
What happened to Biolidics Ltd.’s price movement after its last earnings report?
Biolidics Ltd. reported an EPS of -S$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.308%.
Which hedge fund is a major shareholder of Biolidics Ltd.?
Currently, no hedge funds are holding shares in SG:8YY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biolidics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Biolidics Ltd.
Embracing Future Holdings Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Japan, Hong Kong, Thailand, Malaysia, and the United States. It operates through Cancer, Infectious Diseases, and Laboratory Services segments. The company offers ClearCell FX1 System that includes Streck Cell-free DNA BCT and EDTA tubes, a fully automated device for cell retrieval that can separate wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood; and CTChip FR1 biochip that isolate the CTCs from leukocytes. It also provides laboratory services. The company was formerly known as Biolidics Limited and changed its name to Embracing Future Holdings Limited in June 2025. The company was incorporated in 2009 and is based in Singapore.
Technical Analysis
HC Surgical Specialists Ltd
―
Hyphens Pharma International Ltd.
―
iX Biopharma Ltd.
―
VicPlas International Ltd.
―
Singapore Paincare Holdings Limited
―